Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: A comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method

Histopathology

Volumn 59, Issue 1, 2011, Pages 8-17

  García García, Elena ^a   Gómez Martín, Carlos ^b   Angulo, Bárbara ^a   Conde, Esther ^a   Suárez Gauthier, Ana ^a   Adrados, Magdalena ^c   Perna, Cristian ^c   Rodríguez Peralto, José Luis ^d   Hidalgo, Manuel ^a   López Ríos, Fernando ^a  

^a UNIVERSIDAD SAN PABLO CEU   (Spain)

^b Centro Nacional de Investigations Oncológicas   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Dual colour hybridization; Fluorescence in situ hybridization; Gastric carcinoma; Human epidermal growth factor receptor 2; Silver enhanced in situ hybridization

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; AUTOMATION; DULA COLOUR SILVER IN SITU HYBRIDIZATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GOLD STANDARD; HUMAN; HUMAN TISSUE; HYBRIDIZATION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CARCINOMA;

ADENOCARCINOMA; AUTOMATION, LABORATORY; GENE AMPLIFICATION; GENE DOSAGE; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION; IN SITU HYBRIDIZATION, FLUORESCENCE; REAL-TIME POLYMERASE CHAIN REACTION; SILVER; STOMACH NEOPLASMS;

EID: 79960460895     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03894.x     Document Type: Article

References (43)

1. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235; 177-182.
2. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376; 687-697.
3. Laé M, Couturier J, Oudard S et al. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann. Oncol. 2010; 21; 815-819.
4. Ross HJ, Blumenschein GR Jr, Aisner J, et al. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin. Cancer Res. 2010; 16; 1938-1949.
5. Tubbs RR, Pettay JD, Roche PC et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J. Clin. Oncol. 2001; 19; 2714-2721.
6. Mass RD, Press MF, Anderson S et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence insitu hybridization in women with metastatic breast cancer treated with trastuzumab. Clin. Breast Cancer 2005; 6; 240-246.
7. Arena V, Pennacchia I, Carbone A, Capelli A. Fluorescent insitu hybridization for human epidermal growth factor receptor 2 assessment in breast cancer: is it applicable as a primary test? J. Clin. Oncol. 2009; 27; e83-84.
8. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007; 25; 118-145.
9. Bilous M, Dowsett M, Hanna W et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod. Pathol. 2003; 16; 173-182.
10. Chivukula M, Bhargava R, Brufsky A, Surti U, Dabbs DJ. Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases. Mod. Pathol. 2008; 21; 363-368.
11. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J. Clin. Oncol. 2009; 27; 1323-1333.
12. Phillips KA, Marshall DA, Haas JS et al. Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer 2009; 115; 5166-5174.
13. Allison M. The HER2 testing conundrum. Nat. Biotechnol. 2010; 28; 117-119.
14. Nitta H, Hauss-Wegrzyniak B, Lehrkamp M et al. Development of automated brightfield double insitu hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence insitu hybridization (FISH). Diagn. Pathol. 2008; 3; 41.
15. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J. Clin. Oncol. 2009; 27; 4027-4034.
16. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol. Microbiol. Scand. 1965; 64; 31-49.
17. Tubbs RR, Hicks DG, Cook J et al. Fluorescence insitu hybridization (FISH) as primary methodology for the assessment of HER2 status in adenocarcinoma of the breast: a single institution experience. Diagn. Mol. Pathol. 2007; 16; 207-210.
18. Bartlett JM, Campbell FM, Ibrahim M et al. Chromogenic insitu hybridization: a multicenter study comparing silver insitu hybridization with FISH. Am. J. Clin. Pathol. 2009; 132; 514-520.
19. Layfield LJ, Willmore-Payne C, Isom G, Holden JA. Monoplex LightCycler polymerase chain reaction quantitation of the HER2 gene for quality assurance of HER2/neu testing by immunohistochemistry and fluorescence insitu hybridization. Appl. Immunohistochem. Mol. Morphol. 2008; 16; 562-567.
20. Angulo B, García-García E, Martínez R et al. A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: A morphology-based approach in colorectal carcinoma. J. Mol. Diagn. 2010; 12; 292-299.
21. Hofmann M, Stoss O, Shi D et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52; 797-805.
22. Kanta SY, Yamane T, Dobashi Y et al. Topoisomerase II alpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence insitu hybridization study. Hum. Pathol. 2006; 37; 1333-1343.
23. Gaiser T, Waha A, Moessler F et al. Comparison of automated silver enhanced insitu hybridization and fluorescence insitu hybridization for evaluation of epidermal growth factor receptor status in human glioblastomas. Mod. Pathol. 2009; 22; 1263-1271.
24. Mayr D, Heim S, Weyrauch K et al. Chromogenic insitu hybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic insitu hybridization with immunohistochemistry and fluorescence insitu hybridization. Histopathology 2009; 55; 716-723.
25. Hoff K, Jørgensen JT, Müller S et al. Visualization of FISH probes by dual-color chromogenic insitu hybridization. Am. J. Clin. Pathol. 2010; 133; 205-211.
26. García-Caballero T, Grabau D, Green AR et al. Determination of HER2 amplification in primary breast cancer using dual-color chromogenic insitu hybridization is comparable to fluorescence insitu hybridization: a European multicentre study involving 168 specimens. Histopathology 2010; 56; 472-480.
27. Papouchado BG, Myles J, Lloyd RV. Silver insitu hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility. Am. J. Surg. Pathol. 2010; 34; 767-776.
28. Dietel M, Ellis IO, Höfler H et al. Comparison of automated silver enhanced insitu hybridization (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch. 2007; 451; 19-25.
29. Carbone A, Botti G, Gloghini A et al. Delineation of HER2 gene status in breast carcinoma by silver insitu hybridization is reproducible among laboratories and pathologists. J. Mol. Diagn. 2008; 10; 527-536.
30. Francis GD, Jones MA, Beadle GF, Stein SR. Bright-field insitu hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome. Diagn. Mol. Pathol. 2009; 18; 88-95.
31. Shousha S, Peston D, Amo-Takyi B, Morgan M, Jasani B. Evaluation of automated silver-enhanced insitu hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens. Histopathology 2009; 54; 248-253.
32. Yoo SB, Lee HJ, Park JO et al. Reliability of chromogenic insitu hybridization for epidermal growth factor receptor gene copy number detection in non-small-cell lung carcinomas: a comparison with fluorescence insitu hybridization study. Lung Cancer 2010; 67; 301-305.
33. Pedersen M, Rasmussen BB. The correlation between dual-color chromogenic insitu hybridization and fluorescence insitu hybridization in assessing HER2 gene amplification in breast cancer. Diagn. Mol. Pathol. 2009; 18; 96-102.
34. Hofmann M, Stoss O, Gaiser T et al. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J. Clin. Pathol. 2008; 61; 89-94.
35. Arnould L, Arveux P, Couturier J et al. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. Clin. Cancer Res. 2007; 13; 6404-6409.
36. Dowsett M, Procter M, McCaskill-Stevens W et al. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1year of trastuzumab: the HERA Trial. J. Clin. Oncol. 2009; 27; 2962-2969.
37. Liang Z, Zeng X, Gao J et al. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer 2008; 8; 363.
38. Barros-Silva JD, Leitão D, Afonso L et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br. J. Cancer 2009; 100; 487-493.
39. Marx AH, Tharun L, Muth J et al. HER-2 amplification is highly homogenous in gastric cancer. Hum. Pathol. 2009; 40; 769-777.
40. Bilous M, Osamura RY, Rüschoff J et al. HER-2 amplification is highly homogenous in gastric cancer. Hum. Pathol. 2010; 41; 304-305.
41. Nakhleh RE, Grimm EE, Idowu MO et al. Laboratory compliance with the American Society of Clinical Oncology/College of American Pathologists guidelines for human epidermal growth factor 2 testing. Arch. Pathol. Lab. Med. 2010; 134; 728-734.
42. Gómez-Martín C, Concha A, Corominas JM et al. Consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma. Clin. Transl. Oncol. 2011 (in press).
43. Salto-Tellez M, Yau EX, Yan B, Fox SB. Where and by Whom Should Gastric Cancer HER2/neu Status Be Assessed?: Lessons From Breast Cancer. Arch. Pathol. Lab. Med. 2011; 135; 693-695.